Evaluating a Tailored Cognitive Behavioral Therapy for Adolescent and Young Adult Cancer Patients

• ClinicalTrials.gov Identifier: NCT04773197
• Recruitment Status: Terminated
• First Posted: February 26, 2021
• Last Update Posted: January 10, 2022
• Sponsor: University of Michigan Rogel Cancer Center
• Collaborator: St. Baldrick's Foundation
• Information provided by (Responsible Party): University of Michigan Rogel Cancer Center

Study Description

Brief Summary:

This project's overall goal is to test the feasibility, acceptability and efficacy of two coach-assisted, computer-based, cognitive- behavioral therapy (C-CBT) interventions in treating depression and anxiety in adolescent and young adult cancer survivors. The two coach-assisted interventions will be compared to the standard C-CBT intervention.

Condition or disease	Intervention/treatment	Phase
Depression, Anxiety; Cancer	Behavioral: Beating the Blues (BtB); Behavioral: Entertain Me Well (EMW); Behavioral: Coaching	Not Applicable

Detailed Description:

This will be a three-arm randomized controlled trial with two treatment arms and one control arm. Participants in the first treatment arm will receive a coach-assisted C-CBT intervention called "Beating the Blues" (BtB). A second treatment arm will receive a coach-assisted, animated C-CBT intervention called "Entertain Me Well" (EMW). Both treatment arms will have 8 weekly sessions that contain core components of CBT. A coach will provide between-session support throughout the 8 sessions. The control arm will use the standard care of BtB without coach assistance.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 9 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: This study is a three-arm, prospective randomized controlled trial with participants being randomly assigned into one of the three groups: (1) coach-assisted BtB intervention (treatment condition 1), (2) coach-assisted animated EMW (treatment condition 2), and (3) standard BtB (control group).
• Masking: None (Open Label)
• Primary Purpose: Supportive Care
• Official Title: Evaluating a Tailored Cognitive Behavioral Therapy for Adolescent and Young Adult Cancer Patients
• Actual Study Start Date: November 30, 2020
• Actual Primary Completion Date: August 3, 2021
• Actual Study Completion Date: August 3, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: Coach-assisted C-CBT with BtB; Participants will receive coach- assisted Beating the Blues (BtB), a C- CBT program, which contains 8 weekly sessions. A coach will provide between session support throughout the 8 sessions.	Behavioral: Beating the Blues (BtB); Beating the Blues (BtB) is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.; Behavioral: Coaching; A coach will spend approximately 5-10 minutes after each session with the patient to link the C-CBT content with patient's disease specific experiences and to motivate them to continue the program. They will also spend approximately 5 minutes between sessions to motivate a patient to complete assignments and to remind them about starting the next session on time.
Active Comparator: Coach-assisted animated C-CBT with EMW; Participants will receive coach- assisted Entertain Me Well (EMW), an animated C-CBT program, which contains 8 weekly sessions. A coach will provide between session support throughout the 8 sessions.	Behavioral: Entertain Me Well (EMW); Entertain Me Well (EMW) is is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.; Behavioral: Coaching; A coach will spend approximately 5-10 minutes after each session with the patient to link the C-CBT content with patient's disease specific experiences and to motivate them to continue the program. They will also spend approximately 5 minutes between sessions to motivate a patient to complete assignments and to remind them about starting the next session on time.
Active Comparator: Standard stand-alone C-CBT with BtB; Participants will use the stand-alone BtB for 8 weekly sessions, without coach assistance.	Behavioral: Beating the Blues (BtB); Beating the Blues (BtB) is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.

Outcome Measures

Primary Outcome Measures :

1. Rate of C-CBT completion [ Time Frame: 10 weeks ]
   Percentage of participants in each arm who complete at least 6 out of 8 sessions, as measured by online service usage data.
2. Percentage of participants who confirm acceptability of the intervention during interviews [ Time Frame: 10 weeks ]
   Participants will be interviewed about their perceptions regarding the delivery format, treatment content, and other treatment related factors. Qualitative interviews will be transcribed by research staff and coded using thematic content analysis and axial coding. Qualitative data will be reviewed iteratively until saturation is reached, that is when no new information seems to emerge during coding. Emergence or non-emergence of acceptability theme will be assessed. Findings will be descriptive and will include the percentage of participants who confirm acceptability.

Secondary Outcome Measures :

1. Change in level of depression from baseline to end of intervention [ Time Frame: 10 weeks ]
   The Patient Health Questionnaire, 9 -item (PHQ-9) is a validated brief measure of depression. Participants will answer the questionnaire at their baseline assessment, at the beginning of each session, and at their post-intervention assessment.
2. Change in level of anxiety from baseline to end of intervention [ Time Frame: 10 weeks ]
   The Generalized Anxiety Disorder, 7-item (GAD-7) is a validated brief measure of anxiety. Participants will answer the questionnaire at their baseline assessment and at their post-intervention assessment.
3. Change in level of distress from baseline to end of intervention [ Time Frame: 10 weeks ]
   The Brief Symptom Inventory, 18-item (BSI-18) is a validated distress screening tool especially for cancer patients. Participants will answer the questionnaire at their baseline assessment and at their post-intervention assessment.
4. Change in level of self-efficacy from baseline to end of intervention [ Time Frame: 10 weeks ]
   The PROMIS Self-Efficacy for Managing Chronic Conditions (PROMIS SM Scale) is a 28-item validated tool to assess patients' self-efficacy in managing their chronic condition symptoms.
5. Change in level of involvement and participation in health care from baseline to end of intervention [ Time Frame: 10 weeks ]
   The Patient Activation Measure (PAM) is a 13-item validated tool to evaluate patients' involvement and participation in their health care. Participants will answer the questionnaire at their baseline assessment and at their post-intervention assessment.

Eligibility Criteria

• Ages Eligible for Study: 15 Years to 25 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Cancer survivor, either receiving active treatment or completed cancer treatment
• Experiencing depression and anxiety as measured by PHQ-9 or GAD-7

Exclusion Criteria:

• Severe medical or mental condition (e.g. suicidal ideation)
• Medical condition that prevents patients from operating a computer or tablet
• Receiving end-of-life care

Contacts and Locations

Locations

United States, Michigan

University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, United States, 48109

Sponsors and Collaborators

University of Michigan Rogel Cancer Center

St. Baldrick's Foundation

Investigators

• Principal Investigator: Anao Zhang, Ph.D.; University of Michigan

More Information

• Responsible Party: University of Michigan Rogel Cancer Center
• ClinicalTrials.gov Identifier: NCT04773197
• Other Study ID Numbers: UMCC 2019.159; HUM00165949 ( Other Identifier: University of Michigan )
• First Posted: February 26, 2021
• Last Update Posted: January 10, 2022
• Last Verified: December 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Depression; Behavioral Symptoms